Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
Neomorph, Inc. today announced it has entered into a collaboration and licensing agreement with global healthcare company Novo Nordisk to discover, develop and commercialize molecular glue degraders. ...
Riders from Team Novo Nordisk competing in UCI World Tour races in Quebec City Friday, September 8, and in Montreal on Sunday, September 10 MONTREAL, Sept. 6, 2023 /CNW/ - The Grand Prix Cycliste de...
An initiative supported by a $2M donation from Novo Nordisk MONTREAL, April 5, 2022 /CNW/ - The Réseau d'action en santé cardiovasculaire (RASC, or Cardiovascular Health Action Network), a...
MISSISSAUGA, ON, Nov. 25, 2021 /CNW/ - Novo Nordisk announced today that Health Canada has approved Wegovy™ (semaglutide injection), the first-and-only prescription weight-loss medication with...
Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide...
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the...
New results from the STEP phase 3a clinical trial programme demonstrated weight loss with investigational treatment of once-weekly subcutaneous semaglutide 2.4 mg versus placebo. In the STEP 4 trial, ...
Today, Novo Nordisk announced results from three phase 2 clinical trials for insulin icodec, an investigational once-weekly basal insulin analogue, which were presented during the 56th European...
TORONTO, May 24, 2018 /CNW/ - People with a BMI of over 30, treated with Saxenda® (liraglutide) for weight management, lost an average of 8.1 kg (17.9 lbs) after six months in a real-world clinical...
Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes1 1 in 3 respondents considered themselves to be at low risk of CVD2 1 in 6 respondents had...
Taking Diabetes to Heart is a global online survey for people with type 2 diabetes to gain important insights about their awareness of cardiovascular disease (CVD) Globally, CVD is the most common...
BAGSVÆRD, Denmark, Nov. 14, 2016 /CNW/ - Today, Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and free insulin to ...
This material is intended for medical media only. For journalistic assessment and preparation before publication. TORONTO, June 24, 2015 /CNW/ - Today, at the International Society on Thrombosis and...
BOSTON, MA, June 6, 2015 /CNW/ - This material is intended for medical non-UK media only. For journalistic assessment and preparation before publication Abstract #1121-P New findings showed that...
BAGSVÆRD, Denmark, April 14, 2015 /CNW/ - Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care...
Not intended for UK Media For Healthcare media only SAN FRANCISCO, CA, Dec. 7, 2014 /CNW/ - Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who...
BAGSVÆRD, Denmark, Nov. 14, 2014 /CNW/ - Today, on World Diabetes Day, the Chinese cities of Tianjin and Shanghai join the Cities Changing Diabetes initiative and the global fight against the urban...
MELBOURNE, Australia, Dec. 5, 2013 /CNW/ - Results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™) presented today at a symposium during the World Diabetes Congress of the...
BAGSVÆRD, Denmark, Sept. 20, 2012 /CNW/ - Novo Nordisk today was ranked number 4 on the Science 2012 Top Employer list - up from ninth place last year. The company's 'innovation leadership',...
ZURICH, July 19 /CNW/ - Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern...
COPENHAGEN, Oct. 26 /CNW/ - Novo Nordisk has been awarded a Good Design Award(TM)(1) for NovoTwist(TM), the new needle designed for use with the insulin delivery device FlexPen(R). The needle, which...
MONTREAL, Oct. 22 /CNW/ - New data on patient treatment satisfaction from the LEAD(TM) 6 trial presented on the 22nd October at the 20th World Diabetes Congress (International Diabetes Federation)...
LONDON, Sept. 28 /CNW/ - A recent Lancet article predicted a doubling of new cases of type 1 diabetes in European children aged under 5, and a 70% rise in cases in children under 15 years - an...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.